Researchers review CAR T-Cell results in kids with B-ALL
NCT ID NCT05440409
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those who had prior treatment with blinatumomab. By analyzing past outcomes, researchers hope to improve future use of CAR T-cell therapy in this age group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute (NCI)
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers